Lumida
/CORT
⌘K
Corcept Therapeutics Inc

Corcept Therapeutics Inc

CORT
$112.79USD-1.85%-2.13 today

MARKET CAP

12.2B

P/E (TTM)

322.3x

FWD P/E

DAY RANGE

$109 – $118

52W RANGE

$29
$126

AI Summary

Stalk
Sell NowMedium

Following activation of a Bearish Pivot Point and break below the 9- and 20-day EMAs, CORT exhibits a medium-term bearish bias under a Stage 4 decline. Short-term price shows rejection at these EMAs and the 50-day SMA acting as resistance, with no signs of stabilization or exhaustion. Immediate sell-side engagement into this resistance zone is advised, while a sustained close above the EMAs would invalidate the downside bias.

  • Q2 2026 revenue +32% YoY to $256.1M; raised 2025 guidance to $800M–$850M
  • Korlym sales and LIFYORLI launch boost prescriptions +42.5% YoY
  • Net income plunged to $19.7M from $47.2M YoY amid higher expenses
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$366.0M$401.9M$482.4M$675.0M$761.4M
YoY %+3.4%+9.8%+20.0%+39.9%+12.8%
P / Sales6.8x5.8x5.6x8.5x5.5x
EV / Sales6.7x5.9x5.6x8.5x5.6x
Gross Profit, Adj.$360.7M$396.5M$475.9M$664.2M$748.4M
YoY %+3.6%+9.9%+20.0%+39.6%+12.7%
Margin %98.6%98.7%98.7%98.4%98.3%
EV / Gross Profit6.8x5.9x5.6x8.7x5.7x
EBITDA, Adj.$128.0M$113.9M$108.3M$137.7M$45.9M
YoY %-0.6%-11.0%-4.9%+27.2%-66.6%
Margin %35.0%28.3%22.5%20.4%6.0%
EV / EBITDA19.3x20.7x24.7x41.8x92.4x
EBIT$124.5M$112.6M$107.3M$137.0M$44.8M
YoY %-2.9%-9.5%-4.8%+27.7%-67.3%
Margin %34.0%28.0%22.2%20.3%5.9%
EV / EBIT19.8x20.9x25.0x42.0x94.7x
Net Income$112.5M$101.3M$105.5M$139.7M$98.2M
YoY %+6.1%-10.0%+4.2%+32.5%-29.7%
Net Margin30.7%25.2%21.9%20.7%12.9%
EPS (GAAP)$0.89$0.87$0.94$1.23$0.82
YoY %+4.7%-2.2%+8.0%+30.9%-33.3%